These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 33930201)
1. Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells. Namvar A; Bolhassani A; Javadi G; Noormohammadi Z Fundam Clin Pharmacol; 2021 Dec; 35(6):1055-1068. PubMed ID: 33930201 [TBL] [Abstract][Full Text] [Related]
2. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Namvar A; Bolhassani A; Javadi G; Noormohammadi Z Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650 [TBL] [Abstract][Full Text] [Related]
3. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932 [TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
5. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses. Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516 [TBL] [Abstract][Full Text] [Related]
6. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Yadav R; Zhai L; Tumban E Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975 [TBL] [Abstract][Full Text] [Related]
7. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477 [TBL] [Abstract][Full Text] [Related]
8. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288 [TBL] [Abstract][Full Text] [Related]
9. Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches. Bagheri A; Nezafat N; Eslami M; Ghasemi Y; Negahdaripour M Infect Genet Evol; 2021 Nov; 95():105084. PubMed ID: 34547435 [TBL] [Abstract][Full Text] [Related]
10. Dissection of Capsid Protein HPV 52 to Rationalize Vaccine Designs Using Computational Approaches Immunoinformatics and Molecular Docking. Firdaus MER; Mustopa AZ; Triratna L; Syahputra G; Nurfatwa M Asian Pac J Cancer Prev; 2022 Jul; 23(7):2243-2253. PubMed ID: 35901328 [TBL] [Abstract][Full Text] [Related]
11. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches. Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192 [TBL] [Abstract][Full Text] [Related]
14. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912 [TBL] [Abstract][Full Text] [Related]
15. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748 [TBL] [Abstract][Full Text] [Related]
16. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related]
17. Computational Modeling of Immune Response Triggering Immunogenic Peptide Vaccine Against the Human Papillomaviruses to Induce Immunity Against Cervical Cancer. Ahmad N; Ali SS; Ahmad S; Hussain Z; Qasim M; Suleman M; Ali S; Nizam-Uddin N; Khan A; Wei DQ Viral Immunol; 2021 Sep; 34(7):457-469. PubMed ID: 33973819 [TBL] [Abstract][Full Text] [Related]
18. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098 [TBL] [Abstract][Full Text] [Related]
19. In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design. Ghorban Hosseini N; Tebianian M; Farhadi A; Hossein Khani A; Rahimi A; Mortazavi M; Hosseini SY; Taghizadeh M; Rezaei M; Mahdavi M Viral Immunol; 2017 Apr; 30(3):210-223. PubMed ID: 28388355 [TBL] [Abstract][Full Text] [Related]
20. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Pineo CB; Hitzeroth II; Rybicki EP Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]